Contrast-Enhanced Ultrasound-Guided Liver Tumor Biopsy for Primary Hepatic Angiosarcoma: A Case Series

对比增强超声引导下肝脏肿瘤活检术治疗原发性肝血管肉瘤:病例系列研究

阅读:1

Abstract

Primary hepatic angiosarcoma (PHA) is a rare and aggressive malignant liver tumor that is often difficult to diagnose due to its nonspecific clinical presentation and imaging findings. This case series aimed to illustrate the utility of contrast-enhanced ultrasound (CEUS)-guided percutaneous liver biopsy for the definitive diagnosis of unresectable PHA. We report three patients who presented with nonspecific symptoms and hepatic masses. Imaging findings were inconclusive for a definitive diagnosis, and histopathological evaluation was required. All patients underwent CEUS-guided percutaneous liver tumor biopsy. CEUS enabled real-time visualization of viable tumor regions, facilitating accurate needle placement and minimizing sampling from necrotic or hemorrhagic areas. In Case one, multiple punctures were needed to obtain viable tissue due to extensive necrosis. In Cases two and three, CEUS was particularly useful for demarcating poorly defined lesions, resulting in successful tissue sampling with fewer punctures. Biopsies were performed during the post-vascular phase, enhancing diagnostic yield. Histopathological analysis revealed CD31-positive spindle-shaped cells and a high Ki-67 index, confirming the diagnosis of PHA in all cases. All patients died within six months of diagnosis despite chemotherapy, underscoring the poor prognosis and clinical urgency. CEUS-guided percutaneous liver biopsy is a minimally invasive and reliable technique for the diagnosis of PHA, especially in patients who are not candidates for surgery. This approach enables targeted tissue acquisition, potentially improves diagnostic accuracy, and may contribute to the earlier management of this rare malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。